MX2012006525A - Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que las contienen. - Google Patents
Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que las contienen.Info
- Publication number
- MX2012006525A MX2012006525A MX2012006525A MX2012006525A MX2012006525A MX 2012006525 A MX2012006525 A MX 2012006525A MX 2012006525 A MX2012006525 A MX 2012006525A MX 2012006525 A MX2012006525 A MX 2012006525A MX 2012006525 A MX2012006525 A MX 2012006525A
- Authority
- MX
- Mexico
- Prior art keywords
- cis
- cyclopenta
- pyrrole
- methoxy
- iii
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract 5
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- PUDMRELHLPIHHP-UHFFFAOYSA-N 2-methoxy-1-[2-(2-methoxyacetyl)cyclopentyl]ethanone Chemical compound COCC(=O)C1C(CCC1)C(COC)=O PUDMRELHLPIHHP-UHFFFAOYSA-N 0.000 abstract 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 4
- -1 benzamide compound Chemical class 0.000 abstract 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- QCWDCTDYSDJKTP-UHFFFAOYSA-N 4,5,6,6a-tetrahydro-3ah-cyclopenta[c]pyrrole-1,3-dione Chemical compound C1CCC2C(=O)NC(=O)C21 QCWDCTDYSDJKTP-UHFFFAOYSA-N 0.000 abstract 2
- AFSVOZDCVFYWFG-KBGJBQQCSA-N 4-[3-[(3as,6ar)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]propoxy]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)N)=CC=C1OCCCN1C[C@H]2CCC[C@H]2C1 AFSVOZDCVFYWFG-KBGJBQQCSA-N 0.000 abstract 2
- 229910021529 ammonia Inorganic materials 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 238000006268 reductive amination reaction Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 230000002194 synthesizing effect Effects 0.000 abstract 2
- UZHVXJZEHGSWQV-KNVOCYPGSA-N (3as,6ar)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NC[C@H]2CCC[C@H]21 UZHVXJZEHGSWQV-KNVOCYPGSA-N 0.000 abstract 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 abstract 1
- MRNMYWNBLVJWKG-GASCZTMLSA-N 4-[3-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]propoxy]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCCCN1C[C@H]2CCC[C@H]2C1 MRNMYWNBLVJWKG-GASCZTMLSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 230000002075 anti-alcohol Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000000197 pyrolysis Methods 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Procedimiento de sĆntesis industrial y forma cristalina I del compuesto de fĆ³rmula (1): (ver fĆ³rmula (I)) asĆ como la forma cristalina I de la base libre asociada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1101746A FR2976285B1 (fr) | 2011-06-08 | 2011-06-08 | Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012006525A true MX2012006525A (es) | 2013-01-09 |
Family
ID=46172744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006525A MX2012006525A (es) | 2011-06-08 | 2012-06-07 | Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que las contienen. |
Country Status (44)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3003466B1 (fr) * | 2013-03-22 | 2015-08-07 | Servier Lab | Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques |
| CN103601666B (zh) * | 2013-11-28 | 2015-09-02 | éµä¹å»å¦é¢ | å «ę°¢ēÆęē·[c]å”åÆēå¶å¤ę¹ę³ |
| CN104387313B (zh) * | 2014-10-22 | 2015-12-30 | ę»Øęµ·å大åå·„ęéå ¬åø | äøē§1,2-ēÆęäŗē²é °äŗčŗēå¶å¤ę¹ę³ |
| KR101966221B1 (ko) * | 2017-06-14 | 2019-04-12 | ģµģź·¼ | ģ ķ“ź°ģ¤ ģ²ė¦¬ ģ„ģ¹ |
| CN115232058A (zh) * | 2022-08-01 | 2022-10-25 | äøęµ·å·½ē°ē§ęč”份ęéå ¬åø | äøē§ę ¼åé½ē¹äøé“ä½1,2-ēÆęäŗē²é °čŗēåęę¹ę³ |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US756120A (en) * | 1902-07-28 | 1904-03-29 | Krupp Gmbh | Recoil-gun with special devices for protecting the slide-tracks from dust. |
| NL132376C (es) * | 1966-02-10 | |||
| US4895840A (en) * | 1987-06-10 | 1990-01-23 | A. H. Robins Company, Incorporated | N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or n'n')alkylaminoalkyl ureas and cyanoguanidines |
| CN1314340A (zh) * | 2000-03-21 | 2001-09-26 | å±±äøēå»čÆå·„äøē ē©¶ę | ēÆęē·é °äŗčŗēå¶å¤ę¹ę³ |
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN100424077C (zh) * | 2005-06-07 | 2008-10-08 | å°å·åøåē»“åå·„å | äøē§ēÆęē·1ļ¼2-äŗé °äŗčŗēå¶å¤ę¹ę³ |
| FR2937251B1 (fr) * | 2008-10-16 | 2011-03-18 | Servier Lab | Utilisation du 4-{3-Ā°hexahydrocyclopentaĀ°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil |
| BRPI0921184A2 (pt) * | 2008-11-26 | 2018-03-13 | Abbott Lab | octa-hidriciclopenta[c]pirrol-4-aminas substituĆdas como bloqueadores do canal de cĆ”lcio. |
| FR2953515B1 (fr) * | 2009-12-09 | 2011-12-23 | Servier Lab | Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
-
2011
- 2011-06-08 FR FR1101746A patent/FR2976285B1/fr not_active Expired - Fee Related
-
2012
- 2012-05-22 IL IL219925A patent/IL219925A0/en unknown
- 2012-05-22 PH PH1/2012/000124A patent/PH12012000124A1/en unknown
- 2012-05-22 PE PE2012000695A patent/PE20130046A1/es not_active Application Discontinuation
- 2012-05-23 CR CR20120274A patent/CR20120274A/es unknown
- 2012-05-24 AU AU2012203062A patent/AU2012203062B2/en not_active Expired - Fee Related
- 2012-05-24 TN TNP2012000254A patent/TN2012000254A1/fr unknown
- 2012-05-24 SG SG2012038055A patent/SG186546A1/en unknown
- 2012-05-28 AP AP2012006280A patent/AP2012006280A0/xx unknown
- 2012-05-30 CA CA2779045A patent/CA2779045C/fr not_active Expired - Fee Related
- 2012-05-31 CU CU2012000087A patent/CU20120087A7/es unknown
- 2012-05-31 UY UY0001034110A patent/UY34110A/es unknown
- 2012-06-01 EC ECSP12011941 patent/ECSP12011941A/es unknown
- 2012-06-04 MA MA34937A patent/MA33883B1/fr unknown
- 2012-06-05 BR BRBR102012013573-6A patent/BR102012013573A2/pt not_active IP Right Cessation
- 2012-06-05 GE GEAP201212735A patent/GEP20156395B/en unknown
- 2012-06-05 KR KR1020120060635A patent/KR20120136296A/ko not_active Abandoned
- 2012-06-06 CO CO12095647A patent/CO6580197A1/es unknown
- 2012-06-06 SV SV2012004237A patent/SV2012004237A/es unknown
- 2012-06-06 US US13/489,691 patent/US8664408B2/en not_active Expired - Fee Related
- 2012-06-07 WO PCT/FR2012/051272 patent/WO2012168657A1/fr active Application Filing
- 2012-06-07 GT GT201200182A patent/GT201200182A/es unknown
- 2012-06-07 AR ARP120102010A patent/AR086848A1/es unknown
- 2012-06-07 HU HUE12171118A patent/HUE028050T2/en unknown
- 2012-06-07 RS RS20150642A patent/RS54279B1/en unknown
- 2012-06-07 DK DK12171118.8T patent/DK2532651T3/en active
- 2012-06-07 CL CL2012001500A patent/CL2012001500A1/es unknown
- 2012-06-07 SI SI201230309T patent/SI2532651T1/sl unknown
- 2012-06-07 PT PT121711188T patent/PT2532651E/pt unknown
- 2012-06-07 MD MDA20120049A patent/MD4345C1/ro not_active IP Right Cessation
- 2012-06-07 RU RU2013158817/04A patent/RU2013158817A/ru not_active Application Discontinuation
- 2012-06-07 TW TW101120546A patent/TWI499584B/zh not_active IP Right Cessation
- 2012-06-07 JP JP2012129440A patent/JP5680022B2/ja not_active Expired - Fee Related
- 2012-06-07 EP EP12171118.8A patent/EP2532651B1/fr active Active
- 2012-06-07 ZA ZA2012/04183A patent/ZA201204183B/en unknown
- 2012-06-07 ES ES12171118.8T patent/ES2554933T3/es active Active
- 2012-06-07 ME MEP-2015-148A patent/ME02346B/me unknown
- 2012-06-07 PL PL12171118T patent/PL2532651T3/pl unknown
- 2012-06-07 MX MX2012006525A patent/MX2012006525A/es not_active Application Discontinuation
- 2012-06-08 NI NI201200102A patent/NI201200102A/es unknown
- 2012-06-08 EA EA201200726A patent/EA022741B1/ru not_active IP Right Cessation
- 2012-06-08 CN CN201210189156XA patent/CN102816102A/zh active Pending
-
2013
- 2013-12-11 US US14/103,006 patent/US8952179B2/en not_active Expired - Fee Related
-
2014
- 2014-02-06 US US14/174,272 patent/US20140155453A1/en not_active Abandoned
- 2014-05-27 KR KR1020140063712A patent/KR20140079346A/ko not_active Withdrawn
- 2014-10-31 JP JP2014223181A patent/JP2015044840A/ja active Pending
-
2015
- 2015-10-02 CY CY20151100875T patent/CY1116739T1/el unknown
- 2015-10-09 HR HRP20151073TT patent/HRP20151073T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098260A2 (es) | Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparaciĆ³n, composiciĆ³n y forma purificada | |
| EP4023641A3 (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| MX2012006525A (es) | Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que las contienen. | |
| WO2011048604A3 (en) | Processes for the preparation of darunavir and the amorphous form thereof | |
| NZ595591A (en) | Processes for the preparation of morphinane and morphinone compounds | |
| TW200720366A (en) | Process for preparing metal compounds of an azo compound in the presence of seed crystals | |
| NZ589350A (en) | Novel [F-18]-labelled L-glutamic acid- and L-glutamine derivatives (I), use thereof and method for their production | |
| CO6231027A2 (es) | Metodos e intermediarios para preparar compuestos de lactama lactoma de 8 atomos de carbono activos como inhibidores de renina | |
| NZ613580A (en) | N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes | |
| MY163164A (en) | Ethynyl derivatives as positive allosteric modulators of the mglur5 | |
| CL2010001639A1 (es) | Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina. | |
| ZA201003751B (en) | Process for the synthesis of propargylated aminoindan derivatives | |
| AR051373A1 (es) | Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos | |
| MX2010009926A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico. | |
| MX2010009876A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente. | |
| JO2812B1 (en) | A method of obtaining the aggregate V crystal form of agomelatine | |
| MX2010001512A (es) | Nuevo procedimiento de preparacion. | |
| MX2011011547A (es) | Procedimiento para la preparacion de oxindoles y anilinas orto-sustituidas y su uso como productos intermedios para sintesis. | |
| NZ612592A (en) | Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | |
| MX2011008178A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| MX2010004168A (es) | Procedimiento mejorado para preparar 2-(fenil sustituido)-2-hidroxi-etil carbamatos. | |
| JP2020503330A5 (es) | ||
| WO2015022702A3 (en) | Process for preparation of 4,5-dimethoxybenzene derivatives and use in the synthesis of ivabradine and salts thereof | |
| GEP20156350B (en) | New process for synthesis of ivabradine and their additional salts with pharmaceutically acceptable acid | |
| WO2013124748A4 (en) | Novel polymorphs of azilsartan medoxomil potassium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |